 |
|
Use of Human Immunodeficiency Virus Postexposure Prophylaxis in Adolescent Sexual Assault Victims
Elyse Olshen, MD, MPH;
Katherine Hsu, MD, MPH;
Elizabeth R. Woods, MD, MPH;
Marvin Harper, MD;
Brooke Harnisch, MA;
Cathryn L. Samples, MD, MPH
Arch Pediatr Adolesc Med. 2006;160:674-680.
Objectives To describe the use of human immunodeficiency virus (HIV) postexposure prophylaxis (PEP) in adolescent survivors of sexual assault and to explore barriers to PEP completion in this population.
Design Chart review.
Setting Two academic medical centers in Boston, Mass, between July 1, 2001, and June 30, 2003.
Participants Adolescents presenting to 2 urban pediatric emergency departments within 72 hours of a penetrating sexual assault. Of 177 charts reviewed, adequate documentation of the sexual assault and medical management was available for 145 patients.
Intervention Provision of HIV PEP.
Main Outcome Measure Documented completion of a 28-day course of PEP.
Results Among the 145 patients, 96% were female, 38% were black, and 14% were Hispanic. Many patients were uncertain regarding their exposures: 27% were unsure whether a condom had been used, 54% were unsure whether ejaculation had occurred, and 21% had blacked out during the assault. One hundred ten (76%) received HIV PEP. Of the 97 patients referred for follow-up at the academic centers, 37 returned for at least 1 visit and 13 completed a 28-day course of PEP. Sixteen (46%) of those taking PEP who returned for follow-up developed an adverse reaction to medication. Forty-seven percent of adolescent sexual assault survivors had carried a psychiatric diagnosis before the assault; adherence to PEP was lower among these adolescents.
Conclusions We observed low rates of PEP completion among adolescent sexual assault survivors. Potential difficulties of using PEP in this population include uncertainties regarding exposure, high rates of psychiatric comorbidity, and low rates of return for follow-up care.
Author Affiliations: Divisions of Adolescent Medicine (Drs Olshen and Hsu) and Pediatric Infectious Disease (Dr Hsu and Ms Harnisch), Boston Medical Center, Boston University School of Medicine, Boston, Mass; and Divisions of Adolescent Medicine (Drs Olshen, Woods, and Samples), Pediatric Infectious Disease (Dr Harper), and Pediatric Emergency Medicine (Dr Harper), Children's Hospital Boston, Harvard Medical School. Dr Olshen is now with the Department of Pediatrics, Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia University, New York, NY.
RELATED ARTICLE
Human Immunodeficiency Virus Prophylaxis for Sexual Assault Survivors: What We Need to Know
Jonathan M. Ellen
Arch Pediatr Adolesc Med. 2006;160(7):754-755.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Compliance in Rhode Island Emergency Departments With American Academy of Pediatrics Recommendations for Adolescent Sexual Assaults
Merchant et al.
Pediatrics 2008;121:e1660-e1667.
ABSTRACT
| FULL TEXT
Human Immunodeficiency Virus Prophylaxis for Sexual Assault Survivors: What We Need to Know
Ellen
Arch Pediatr Adolesc Med 2006;160:754-755.
FULL TEXT
|
